F5
ENSG00000198734
Target class
Secreted protein
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Other names
- fV
- Target name
- F5
- Gene name
- Coagulation factor V
- Gene symbol
- F5
- Protein name
- Coagulation factor V (Activated protein C cofactor) (Proaccelerin, labile factor) [Cleaved into: Coagulation factor V heavy chain; Coagulation factor V light chain]
- Gene biotype
- Protein coding
- Gene family
- Multicopper oxidase family
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 17
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 34.18
- Tissue specificity (Gini)
- 0.787
- Tissue specificity (tau)
- 0.965
- KEGG gene identifiers
- hsa:2153
- Protein interaction confidence
- 0.811909
- Protein interaction partners
- 22
- R-HSA-114608
- R-HSA-204005
- R-HSA-381426
- R-HSA-5694530
- R-HSA-8957275
- R-HSA-9769735
- R-HSA-9769739
- R-HSA-9769743
- R-HSA-9930449
- R-HSA-9930479
- End position
- 169586588
- Start position
- 169511951
- Chromosome
- 1
- Strand
- Reverse
- Secreted .
- Golgi apparatus
- Tissue specificity (tau)
- 0.965228
- Expression inequality (Gini)
- 0.786855
Expression in transcripts per million
- Liver
- 34.18
- Whole Blood
- 19.21
- Minor Salivary Gland
- 8.43
- Pituitary
- 3.86
- Spleen
- 3.68
Expression in transcripts per million
- Liver34.18
- Whole Blood19.21
- Minor Salivary Gland8.43
- Pituitary3.86
- Spleen3.68
- Lung2.1
- Skin - Sun Exposed (Lower leg)2.05
- Artery - Tibial1.93
- Heart - Atrial Appendage1.88
- Testis1.64
- Kidney - Cortex1.39
- Artery - Coronary1.37
- Heart - Left Ventricle1.18
- Adipose - Visceral (Omentum)1.13
- Skin - Not Sun Exposed (Suprapubic)1.1
- Bladder1.01
- Adipose - Subcutaneous1
- Fallopian Tube0.92
- Thyroid0.86
- Prostate0.8
- Artery - Aorta0.63
- Breast - Mammary Tissue0.52
- Pancreas0.44
- Small Intestine - Terminal Ileum0.4
- Kidney - Medulla0.4
And 29 more, listed on the interactive page.
Biological processes
- GO:0007596
- GO:0005576
- GO:0005788
- GO:0005886
- GO:0016020
- GO:0030134
- GO:0031093
- GO:0033116
- GO:1903561
Molecular functions
- GO:0005515
Related records
Trials (293)
- "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia
- 5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients
- A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
- A Clinical Study on the Improvement of Sleep Quality, Skin Condition and Life Status After Taking Sleep Aid Drinks
- A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
- A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
- A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
- A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus
- A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With Placebo
- A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
- A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
- A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain
- A Study of A-101 Topical Solution for the Treatment of Common Warts
- A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis
- A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
- A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
- A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Drugs (1)
- Drotrecogin alfa (activated) Coagulation factor V inhibitor